<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098615</url>
  </required_header>
  <id_info>
    <org_study_id>F150408010</org_study_id>
    <nct_id>NCT03098615</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Effect of Jublia on Dermatophytomas</brief_title>
  <official_title>An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine how Jublia affects dermatophytomas, which are difficult to treat with
      other therapeutic options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dermatophytomas are known to be resistant to even long courses of systemic antifungals, and
      have therefore been excluded from both topical and systemic clinical trials for
      onychomycosis, including those for Efinaconazole solution. Efinaconazole (Jublia) 10%
      solution is an FDA approved topical medication indicated for treatment of distal lateral
      subungual onychomycosis (DLSO), and the utility of this medication likely exceeds published
      results. Efinaconazole solution's novel ability to penetrate into the subungual space likely
      accounts for improved treatment results seen in DLSO treated with Jublia. We will investigate
      the utility of topical efinaconazole solution in the treatment of dermatophytomas.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Topical application of Jublia (Efinaconazole 10% Topical Solution) to patients with distal lateral subungual onychomycosis with dermatophytoma.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO)</measure>
    <time_frame>week 48</time_frame>
    <description>Clear nail growth between the proximal nail fold and the dermatophytoma's proximal edge will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical or Mycological Cure of Nail</measure>
    <time_frame>week 48</time_frame>
    <description>Completely normal nail plate or negative fungal culture</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Onychomycosis</condition>
  <condition>Dermatophytosis</condition>
  <arm_group>
    <arm_group_label>Jublia (Efinaconazole 10% Topical Solution) + nail polish</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jublia (Efinaconazole 10% Topical Solution)</intervention_name>
    <description>Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.</description>
    <arm_group_label>Jublia (Efinaconazole 10% Topical Solution) + nail polish</arm_group_label>
    <other_name>Jublia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has the informed consent been signed and patient's questions answered.

          -  Age &gt;= 18

          -  Patient willing and able to participate for the full duration of the study

          -  No onychomycosis

          -  Greater than 4 weeks from prior major surgery for any indication

          -  Willing to abstain from:

        The application of other topical medications or cosmetic products to the toenail
        Professional pedicures for the duration of the study. - Females of childbearing potential
        must: Have been using adequate contraception (abstinence, intrauterine device (IUD), birth
        control pills or spermicidal gel with diaphragm or condom) since their last menses Agree to
        continue using adequate means of contraception (abstinence, IUD, birth control pills or
        spermicidal gel with diaphragm or condom) for the duration of study participation

        Females are not considered to be of childbearing potential if they are at least 1 year
        postmenopausal or have had a tubal ligation, bilateral oophorectomy or hysterectomy.

        Exclusion Criteria:

          -  Active onychomycosis of the toenails or fingernails

          -  Any of the following in the 4 weeks (or as indicated) prior to randomization:

        Major surgery for any indication

        - Any personal history of: Invasive cancer diagnosed or treated within the past 5 years.
        Participants who have been in remission for 5 years or more and have not required treatment
        in the past 5 years may be eligible if the principal investigator believes there is little
        to no risk of recurrence.

          -  Concurrent use of the following medications or treatments Other topical antifungals
             for any concomitant infection

          -  Females who are pregnant or lactating. Should a woman become pregnant or suspect she
             is pregnant while she is participating in this study she should notify the study
             physician immediately.

          -  Uncontrolled concurrent illness including ongoing or active infection, psychiatric
             illness/social situations that would limit compliance with study requirements or other
             underlying serious medical condition which, in the investigator's opinion, might
             preclude study participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boni E Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>February 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2019</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Boni Elewski, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
    <mesh_term>Tinea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efinaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03098615/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Jublia Treatment Group</title>
          <description>The intervention to be administered is Jublia (Efinaconazole 10% Topical Solution). The frequency of administration is daily to the affected toes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Group</title>
          <description>Subject with age &gt;18, provision of informed consent, presence of dermatophytoma on one or both great toenails, target great to-nail thickness &lt;= 3.0 mm, positive potassium hydroxide (KOH) or culture. Exclusion based upon history of immunosuppression, history of psoriasis of the nail, other nail disease, 3 or more dermatophytomas, unwillingness to avoid nail polish</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO)</title>
        <description>Clear nail growth between the proximal nail fold and the dermatophytoma's proximal edge will be measured.</description>
        <time_frame>week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Group</title>
            <description>Subject with age &gt;18, provision of informed consent, presence of dermatophytoma on one or both great toenails, target great to-nail thickness &lt;= 3.0 mm, positive KOH or culture. Exclusion based upon history of immunosuppression, history of psoriasis of the nail, other nail disease, 3 or more dermatophytomas, unwillingness to avoid nail polish.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO)</title>
          <description>Clear nail growth between the proximal nail fold and the dermatophytoma's proximal edge will be measured.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical or Mycological Cure of Nail</title>
        <description>Completely normal nail plate or negative fungal culture</description>
        <time_frame>week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Jublia (Efinaconazole 10% Topical Solution) + Nail Polish</title>
            <description>Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
Jublia (Efinaconazole 10% Topical Solution): Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical or Mycological Cure of Nail</title>
          <description>Completely normal nail plate or negative fungal culture</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baseline Group</title>
          <description>Subject with age &gt;18, provision of informed consent, presence of dermatophytoma on one or both great toenails, target great to-nail thickness &lt;= 3.0 mm, positive KOH or culture. Exclusion based upon history of immunosuppression, history of psoriasis of the nail, other nail disease, 3 or more dermatophytomas, unwillingness to avoid nail polish</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leslie Roop</name_or_title>
      <organization>UAB</organization>
      <phone>2059754917</phone>
      <email>lmroop@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

